CCP
JAZZ icon

Carmel Capital Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Carmel Capital Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-30
Closed -$3.88K – 426
2023
Q3 		$3.88K Buy
+30
New +$4K ﹤0.01% 574

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Carmel Capital Partners's JAZZ Position: Q4 2023 in Review

Carmel Capital Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2023, closing a stake of 30 shares — an estimated $3.88K sold.

Carmel Capital Partners first reported a position in JAZZ in Q3 2023 and held it in 1 quarter. The position peaked at $3.88K in Q3 2023. 499 funds tracked by Wall St. Rank hold JAZZ as of Q4 2023.

  • Carmel Capital Partners reported no remaining Jazz Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Carmel Capital Partners sold 30 Jazz Pharmaceuticals shares in Q4 2023, an estimated $3.88K.
  • Carmel Capital Partners first reported a position in Jazz Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Carmel Capital Partners's Jazz Pharmaceuticals position peaked at $3.88K in Q3 2023.
  • 499 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2023.

Based on Carmel Capital Partners's 13F filing for Q4 2023, filed 1 Feb 2024.